Bengaluru-based biotechnology startup CrisprBits has successfully raised $3 million in a Pre-Series A funding round, bringing its valuation to $12 million.
The round was led by Spectrum Impact, the family office of Rajendra Gogri, Chairman and Managing Director of Aarti Industries. Existing investors, including the Vijay Alreja Family Office (VJ Technologies Group), also participated. New investment came from the promoter family of HBL Engineering. The company had previously secured capital from its founders, VJ Technologies Group, and C-CAMP.
Strategic Use of Funds
CrisprBits will strategically utilize the capital to:
-
Scale commercialization of its PathCrisp molecular diagnostics platform.
-
Expand manufacturing for tests targeting human health, food safety, and animal health.
-
Develop a CRISPR-driven strain engineering platform, initially focusing on biofuel production processes.
Company Profile and Future Plans
Founded by Vijay Chandru, Sunil Arora, Rajeev Kohli, Bharat Jobanputra, and Aditya Sarda, CrisprBits runs a 7300 sq ft CRISPR R&D and prototype development facility in Bengaluru. The company operates three core platforms:
-
PathCrisp: Molecular diagnostics.
-
EdiCrisp: Gene editing and strain engineering.
-
CurieCrisp: Preclinical and rare disease-focused therapeutics.
Over the next six months, the biotech firm plans for significant global expansion, aiming to introduce its CRISPR diagnostic products to markets in Africa and Latin America. The company will also focus on scaling infrastructure and production capabilities at its diagnostics manufacturing facility and building an AI-augmented strain engineering platform for sustainability applications.
By: Sandhya Bharti
